View Older Stories

Jan 22, 2026 09:39AM UBS Reiterates Buy Rating on ResMed (RMD) as U.S. Operating Environment Is Supportive

Dec 18, 2025 04:02AM ResMed (RMD) PT Lowered to $260 at Stifel

Dec 16, 2025 03:50AM Baird Downgrades ResMed (RMD) to Neutral

Dec 12, 2025 09:38AM ResMed (RMD) PT Raised to $345 at UBS

Dec 1, 2025 10:07AM Goldman Sachs Adjusts APAC Director's Cut Names in December Update

Nov 20, 2025 02:32PM ResMed (RMD) spreader of 5530 contracts of January 230 and 3160 contracts of July 200 puts

Nov 18, 2025 03:14PM ResMed (RMD) spreader of November 250, December 220 and December 240 puts

Oct 30, 2025 04:47PM ResMed (RMD) Tops Q1 EPS by 3c

Oct 21, 2025 04:24AM ResMed (RMD) PT Raised to $304 at Morgan Stanley

Sep 25, 2025 07:31AM Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'

Sep 18, 2025 06:41AM Citi Starts ResMed (RMD) at Buy

Sep 17, 2025 05:28AM KeyBanc Reiterates Overweight Rating on ResMed (RMD)

Sep 16, 2025 09:43AM UBS Reiterates Buy Rating on ResMed (RMD) Following GLP-1 Survey

Aug 4, 2025 05:24AM CLSA Downgrades ResMed (RMD:AU) (RMD) to Hold (3)

Aug 1, 2025 10:16AM ResMed (RMD) PT Raised to $300 at RBC Capital

Aug 1, 2025 09:07AM ResMed (RMD) PT Raised at KeyBanc; 'Carrying GM Momentum into FY26'

Aug 1, 2025 08:40AM ResMed (RMD) PT Raised to $290 at Mizuho

Aug 1, 2025 06:08AM ResMed (RMD) announces resignation of chief commercial officer

Jul 31, 2025 05:12PM ResMed (RMD) Tops Q4 EPS by 7c

Jul 31, 2025 04:53PM ResMed (RMD) Tops Q4 EPS by 7c

Jul 22, 2025 05:14AM ResMed (RMD:AU) (RMD) PT Raised to AUD44.50 at CLSA

Jul 15, 2025 03:06PM Apple (AAPL) announces hearing aid features, sleep apnea notifications for products

Jul 15, 2025 06:40AM RBC Capital Upgrades ResMed (RMD) to Outperform

Jun 17, 2025 07:05AM KeyBanc Reiterates Overweight Rating on ResMed (RMD)

Jun 13, 2025 08:26AM Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names

Jun 2, 2025 05:48AM ResMed (RMD:AU) (RMD) PT Raised to AUD45 at Citi, Removes 90-Day Downside Catalyst Watch

May 20, 2025 08:49AM UBS Reiterates Buy Rating on ResMed (RMD)

Apr 24, 2025 10:22AM Stifel Reiterates Hold Rating on ResMed (RMD)

Apr 24, 2025 09:21AM ResMed (RMD) PT Raised to $255 at RBC Capital, Citing 'Robust Growth And Tariff Exemptions'

Apr 24, 2025 08:28AM ResMed (RMD) PT Lowered to $248 at Piper Sandler Following 'Mixed FQ3 Print'

Apr 24, 2025 08:17AM ResMed (RMD) PT Raised to $274 at KeyBanc; 'No Longer as Tariff-ied'

Apr 24, 2025 06:59AM ResMed (RMD) PT Lowered to $250 at Mizuho

Apr 24, 2025 06:34AM Oppenheimer Reiterates Perform Rating on ResMed (RMD)

Apr 23, 2025 04:53PM ResMed (RMD) Misses Q3 EPS by 2c

Mar 5, 2025 07:31AM Citi Upgrades ResMed (RMD:AU) (RMD) to Buy

Mar 4, 2025 05:03PM ResMed (RMD) PT Lowered to $240 at Stifel

Mar 3, 2025 05:01AM Zai Lab Limited (ZLAB) and ResMed (RMD) Added to Goldman APAC Director's Cut Conviction List

Jan 31, 2025 10:27AM ResMed (RMD) PT Raised to $247 at RBC after 'Another Quarter of Good Operational Performance'

Jan 31, 2025 09:12AM Stifel Reiterates Hold Rating on ResMed (RMD)

Jan 31, 2025 08:20AM ResMed (RMD) PT Raised to $260 at Piper Sandler; 'FQ2 Print Solid Across-The-Board'

Jan 31, 2025 08:00AM ResMed (RMD) PT Raised to $280 at KeyBanc after a 'Positive 2Q25 Driven by Devices'

Jan 31, 2025 06:03AM Oppenheimer Reiterates Perform Rating on ResMed (RMD)

Jan 31, 2025 06:02AM Needham Reiterates Hold Rating on ResMed (RMD)

Jan 30, 2025 04:34PM ResMed (RMD) Tops Q2 EPS by 11c

Jan 16, 2025 04:35AM Goldman Sachs Starts ResMed (RMD:AU) (RMD) at Buy

Jan 10, 2025 05:12AM Piper Sandler Starts ResMed (RMD) at Neutral

Dec 12, 2024 04:08PM Stifel Starts ResMed (RMD) at Hold

Oct 25, 2024 06:15AM Needham Reiterates Hold Rating on ResMed (RMD)

Oct 24, 2024 04:15PM ResMed (RMD) Tops Q1 EPS by 15c

Oct 10, 2024 05:41AM JPMorgan Reiterates Overweight Rating on ResMed (RMD)

View Older Stories